Hypogonadal men share a variety of signs and symptoms such as decreased muscle mass, osteopoenia, increased fat mass, fatigue, decreased libido and cognitive dysfunctions. Controlled trials have demonstrated favourable effects of androgen substitution therapy on these signs and symptoms in men with severe primary or secondary hypogonadism. Thus, androgen substitution therapy is warranted in men with true hypogonadism at all ages. Symptoms experienced by otherwise healthy ageing males are non-speci®c and vague, although some may be similar to symptoms of hypogonadism. Therefore, the term`andropause' has been suggested. However, testosterone levels show no or only modest variation with age in men; with large prospective studies suggesting a maximal decline of total testosterone of 1.6% per year. Thus, in contrast to the sudden arrest of gonadal activity in females around menopause, men do not have an andropause. As large placebo-controlled studies of androgen treatment in elderly males are lacking, proper risk assessment of adverse effects such as prostate cancer following testosterone treatment in elderly males is completely lacking. In the future, testosterone therapy may prove bene®cial in some elderly males with low±normal testosterone levels. However, at this point in time, widespread use of testosterone in an elderly male population outside controlled clinical trials seems inappropriate.
Introduction
Androgen substitution therapy in young men with primary or secondary hypogonadism has been used for years and can be considered evidence-based. Also androgen substitution therapy in elderly males with severe hypogonadism has proven bene®cial. Clinical signs and symptoms of hypogonadism consist of physical and psychological symptoms such as decreased muscle mass and bone density, increased subcutaneous and abdominal fat mass, fatigue, decreased energy level, decreased libido and cognitive dysfunctions. Androgen substitution therapy improves all of these symptoms in severely hypogonadal males, and is therefore warranted at all ages.
Symptoms experienced by elderly males are non-speci®c and vague, although some may be similar to symptoms of hypogonadism. Therefore, it has been suggested that the slightly decreasing testosterone levels with ageing could account for some of these symptoms. In line with this hypothesis, the term`andropause' has been suggested for men, although no accurate de®nition for this term exists. Alternative names for andropause have been suggested including mid-life crisis, male menopause, androgen de®ciency in ageing males (ADAM) or partial androgen de®ciency in ageing males (PADAM). Furthermore, possible effects of pharmacological testosterone treatment in otherwise healthy elderly males with some symptoms of ageing and testosterone levels in the low±normal range have been argued for, in analogy with effects of estrogen replacement therapy in peri-menopausal women. However, there are no signi®cant associations between endogenous testosterone levels and`andropausal' symptoms in a healthy male population, no consensus exists on the cut-off value for testosterone beyond which therapy should be initiated, and it is not clear if total or free testosterone are to be measured. Testosterone values indicating therapy depend on the normal range of testosterone values which may depend on age as well as on the testosterone assay. Unlike in women where the presence of regular menses indicates normal gonadal function, we have no speci®c clinical criteria in men to de®ne normal and abnormal states. Finally, few controlled studies of androgen treatment in elderly males have been published. For these reasons many authors have questioned the value of androgen replacement in this population.
The key issue is to determine whether partial de®ciency of circulating androgens is a physiological cause of the ageing process in men and whether androgen therapy might prevent or ameliorate a decline in quality of life associated with the agerelated decline in physical and psychological functioning. The present paper will review this area and try to answer and discuss the following important questions: (i) Do serum testosterone levels decline with increasing age and do they relate to the process of ageing? (ii) How is hypogonadism de®ned and how should testosterone be measured (total or free)? (iii) What are the effects of testosterone substitution in hypogonadal males? (iv) Is there evidence of bene®cial effects of testosterone treatment in elderly males with subnormal testosterone? (v) What are the potential side-effects of testosterone therapy?
Male andropause: fact or ®ction?
In women, ovarian sex steroid production stops abruptly at~50 years of age, resulting in a rapidly decreasing serum estradiol (E 2 ) level and cessation of menstrual bleedingÐthe so-called menopause. Menopausal changes in women may be associated with hot ushes, mood changes, vaginal dryness and decreased libido which occur in~30% of all peri-menopausal women. Hormone replacement therapy (HRT) in the peri-menopausal years has gained widespread popularity among women as HRT may overcome some of the above symptoms. In addition, HRT may prevent osteoporosis (Kiel et al., 1987) while the effect of HRT in secondary prevention in women with existing ischaemic heart disease seems uncertain (Hulley et al., 1998; Herrington et al., 2000) . The novel prevocative ®nding that the overall health risks exceeded the bene®ts from use of combined estrogen plus progestin among 16608 healthy women who participated in a large randomized trial (Writing Group for the Women's Heath Initiative Investigators, 2002) emphasize the importance of large controlled trials.
In contrast to post-menopausal women, reproductive function remains relatively intact in ageing men. Nevertheless, some men may experience the same symptoms as climacteric women. Thus, hot¯ushes, sweating, decreased libido, erectile dysfunction, psychomotoric instability, tiredness and decreased vigour are experienced by some elderly men. In a questionnaire investigation among randomly selected Danish middle-aged men, 41% of the 40 year old men answered that a male climacterium did exist, whereas only 30% of 50 year old men believed the andropause to exist (Solstad and Garde, 1992) . Only 4% of 439 healthy 51 year old men replied that they had some form of erectile dysfunction, and had been in contact with the health system because of this (Solstad and Hertoft, 1993) . A subgroup of these men (n = 100) was interviewed in more detail, and almost 40% described varying degrees of sexual dysfunction; only 7% considered this abnormal for their age (Solstad and Hertoft, 1993) . Eighteen per cent had experienced symptoms such as¯ushing and sweating, psychomotoric instability and tiredness, while only 3% reported decreased libido. Interestingly, no differences in free testosterone and LH levels could be found between asymptomatic men and those men describing symptoms such as erectile dysfunction (Feldman et al., 1994) , cognitive and psychological functioning or quality of life (Perry et al., 2001) . Results from the Massachusetts Male Ageing Study (MMAS) suggested that age per se may be a relatively unimportant contributor; endocrine variability and anthropometrics and lifestyle phenomena may be at least as important (McKinlay et al., 1989) . Consequently, the feeling of being climacteric in men is not likely to be due to changes in endogenous testosterone or age, but is probably more closely linked to their opinion of whether or not an andropause exists, as well as to psychosocial changes.
Testosterone production
Testosterone is produced in the testicular Leydig cells and is stimulated by the pituitary LH secretion. In young adults, there is a marked diurnal variation in testosterone levels with morning levels being~20±30% higher than evening levels (Carlsen et al., 1999) . In ageing men the diurnal variation diminishes (Bremner et al., 1983) . In serum, testosterone is bound to sex hormone-binding globulin (SHBG) and albumin, leaving only a minor fraction (2%) of testosterone in its free biologically active form. At the cellular level testosterone is converted to dihydrotestosterone (DHT) by 5a reductase activity, both of which bind to the androgen receptor (AR). Testosterone may also be converted by aromatase (encoded by the CYP19 gene) to E 2 which subsequently activate estrogen receptors (ERa and ERb). Thus, the biological actions of testosterone can be accounted for through activation of the AR, but also through converted E 2 which activates the ER. The biological actions show some variation which can be explained by naturally occurring polymorphisms in the AR gene (e.g. the number of the CAG trinucleotide repeats) as well as in the ER gene.
Changes in testosterone with age
The course of sex steroids in middle-aged men has drawn interest in recent years because of the advent of hormone replacement with testosterone. Nevertheless, there is debate as to whether or not total and free testosterone decline with increasing age, and, if so, to what extent, as discussed in a meta-analysis of 88 studies who evaluated the age±testosterone relationship (Gray et al., 1991) . Several methodological issues may account for some of these discrepancies, such as selection biases inherent in clinicbased research or volunteer enrolment, diurnal variation which was not taken into account as well as the use of different assays. Several cross-sectional studies have shown that testosterone levels are lower in elderly compared with younger men (Vermeulen et al., 1972; Pirke and Doerr, 1975; Baker et al., 1976; Purifoy et al., 1981; Tenover et al., 1987) . These studies have come to a consensus on an~0.4±1.2% annual decrease in total testosterone. However, other cross-sectional studies did not detect lower levels in elderly males compared to younger males as shown in (Figure 1 ). Clearly no difference between young and ageing men is apparent for total testosterone, whereas SHBG increases and free androgen index shows a sign®cant decrease with increasing age. Similarly, LH levels increase slightly (1.3% per year) with increasing age Feldman et al., 2002) .
A few longitudinal studies have evaluated the age-related changes in serum testosterone levels Zmuda et al., 1997; Harman et al., 2001) . Harman et al. (2001) studied testosterone levels in 890 generally healthy men who were followed prospectively. They reported an individual decrease in total testosterone of ±0.11 nmol/l per year (~1% per year) in agreement with others (Zmuda et al., 1997) . Thus, the age-related decrease in serum testosterone was modest. A very interesting study of >1100 men who were followed prospectively for 7±10 years as part of the MMAS (Feldman et al., 2002) found a 0.8% decrease of total testosterone per year when their data were analysed cross-sectionally, whereas the decline was somewhat steeper (1.6% per year) when analysed longitudinally.
Measurement of testosterone
Numerous commercially available kits for determination of total testosterone are on the market. Different kits give comparable results, although differences in actual concentrations are present (Boyle et al., 1984; Ismail et al., 1986) . Thus each laboratory should de®ne its own assay-and population-speci®c normal range for testosterone. All in-house assays and some commercial kits employ a solvent extraction to remove testosterone from endogenous binding proteins and to remove steroid conjugates in the extract prior to radioimmunoassay. Sensitivities of available testosterone assays vary substantially, but sensitivity may be reduced by using a larger volume of serum, increasing the incubation time or other modi®cations (Sinha-Hikim et al., 1998). Furthermore, it has been recommended that testosterone determinations are carried out in specialized laboratories. All measurements should be done in duplicates, and the laboratory should particpate in external quality control programmes (Ismail et al., 1986) . Although steroids are generally considered to be stable upon storage, the in¯uence of storage at room temperature may in¯uence the testosterone results (Kley and Rick, 1984) . Many assays for determination of free testosterone have been described and are currently published although they may never have been validated. Due to the variation of SHBG it is a sound principle to estimate the free biologically active fraction of testosterone in subjects suspected of hypogonadism. In some situations, free testosterone (determined by equilibrium dialysis) levels may correlate better with the clinical situation (such as in hirsutism) compared with total testosterone (Boyle et al., 1984) . Free testosterone can be determined by laborious techniques involving equilibrium dialysis, chromatography (Lavoie et al., 1989; Torma et al., 1995; Sinha-Hikim et al., 1998) or ultra®ltration (Green and Yucis, 1982) followed by radioimmunoassay. Vermeulen et al. found that the free testosterone levels estimated from total testosterone and SHBG levels was a rapid, simple and reliable index of bioavailable testosterone which compared well to levels obtained after equilibrium dialysis (Vermeulen et al., 1999) . Lesstime-consuming techniques and easy-to-use assays have been sought. Such direct easy-to-use assays are available, but the different methodologies have never been subject to peer review. Despite the fact that these assays have never been properly validated, normal ranges have been published for these assays (Ooi et al., 1998; Winters et al., 1998; Kratzsch et al., 2001) and they are commonly used in clinical and experi-mental studies. Importantly, several authors found that free testosterone values obtained by an easy-to-use direct immunoassay were highly inaccurate, greatly underestimating the true levels (Giraudi et al., 1988; Vermeulen et al., 1999) . In line with these ®ndings, two frequently used kits to determine free testosterone were recently severely criticized as being inaccurate and not correlating linearly with values obtained after equilibrium dialysis. The use of such kits to determine free testosterone was therefore strongly discouraged (Rosner, 2001 ).
De®nition of hypogonadism
Hypogonadal males often complain of physical and psychological symptoms such decreased muscle mass, increased subcutaneous and abdominal fat mass, fatigue, decreased energy level, decreased libido and cognitive dysfunctions. Screening questionnaires constructed to evaluate androgen de®ciency showed a relatively poor speci®city of 60% upon validation . De®nition of hypogonadism by hormone measurements is straightforward in cases of completely absent testosterone secretion, although these are rare. More frequently, decreased testosterone levels are to be judged as low±normal or subnormal. The endocrine diagnosis of hypogonadism can be supported by clinical and genetic/chromosomal evaluation in cases of pituitary disease (such as Kallman's syndrome, pituitary stalk interruption syndrome, irradiation etc) as well as in cases of primary testicular disease (such as Klinefelter's syndrome). From Figure 1 it can be seen that the lower normal limit for total testosterone is~8 nmol/l at all ages (Gyllenborg et al., 2001) , whereas even lower cut-off values were described in the MMAS with slightly less than 6 nmol/l being the lower limit (±2 SD) for healthy males aged 40± 70 years (Feldman et al., 2002) . Harman et al. reported that 12, 19 and 28% of males aged 50, 60 and 70 years respectively had testosterone levels <11.3 nmol/l (equal to ±2 SD for 20±40 year old men) . Using similar criteria, the percentage of ageing men classi®ed as hypogonadal by the use of free testosterone was even higher. In many of the small uncontrolled trials of testosterone therapy in ageing males, hypogonadism was de®ned as having a total testosterone below 10 or 11 nmol/l. However, none of the above-mentioned studies evaluated whether those ageing men with testosterone levels between 6 (±2 SD for ageing men) and 11.3 nmol/l (±2 SD for young men) had any signs resembling hypogonadism. As it stands, testosterone levels must be identi®ed as normal when levels are above 6 or 8 nmol/l in ageing men. Clearly, using 10 or 11 nmol/l as the cut-off value misclassi®es a large proportion of elderly men as hypogonadal when they actually represent normality. The use of free testosterone measurement in the diagnosis of hypogonadism is even more uncertain. Although detailed reference ranges exist for free testosterone determined by commercially available kits (Ooi et al., 1998) , methodological problems with these assays remain.
Testosterone effects on target organs
Testosterone and muscle strength Endogenous testosterone is associated with muscle mass and strength in healthy young and elderly males (Ramos et al., 1998; Baumgartner et al., 1999; van den Beld et al., 2000) , but continuous strength training per se does not change testosterone levels (Craig et al., 1989) . Many of the muscle strength tests (such as isometric muscle strength) probably do not correlate well with functional improvements that would result in prevention of falls, ability to perform daily tasks and to live independently, as highlighted in the recent report from the National Institute on Aging Advisory Panel on Testosterone replacement in men (Anonymous, 1997) . Treatment with high dose testosterone (300± 600 mg testosterone enanthate per week) combined with strength training resulted in signi®cantly increased muscle mass in healthy male subjects after 10±12 weeks of therapy (Bhasin et al., 1996; Giorgi et al., 1999) . However, available controlled trials in which elderly males were treated with testosterone in conventional doses showed little effect (or even no effect) on muscle strength (Tenover, 1992; Sih et al., 1997; Snyder et al., 1999b Snyder et al., , 2000 Wang et al., 2000b; Kenny et al., 2001; Ferrando et al., 2002) . Few studies have evaluated whether changes in measured isometric muscle strength in¯uence functional status. Perry et al. found that endogenous testosterone levels correlate with isometric muscle strength as well as with functional ability in elderly males (Perry et al., 2001 ).
Testosterone and bone density
Delayed puberty in boys results in decreased bone mineralization in adult life (Finkelstein et al., 1998) . Hypogonadal men have decreased bone mineral density (BMD) (Finkelstein et al., 1987) , which results in increased fracture risk (Swartz and Young, 1988) . Epidemiological studies of elderly men have demonstrated that testosterone levels are positively correlated with BMD, even though conversion to E 2 seems to be more important for BMD (Greendale et al., 1997; Barrett-Connor, 2000; Khosla et al., 2001) , as evidenced by the severe osteoporosis in a man with normal testosterone levels but with estrogen resistance due to a mutated estrogen receptor (ERa) (Smith et al., 1994) . Likewise, subnormal E 2 levels were seen in 37 out of 63 osteoporotic men whereas only two had subnormal testosterone levels . Furthermore, it has been demonstrated that polymorphisms in the ER gene are associated with osteoporotic fractures in men (Langdahl et al., 2000) . In ageing males, E 2 is the dominant sex steroid regulating bone resorption, whereas both E 2 and testosterone are important in maintaining bone formation (Falahati-Nini et al., 2000) . The effect of testosterone treatment on BMD seems to be dependent on the degree of hypogonadism. Elderly men with a basal testosterone of 13.9 nmol/l showed no change in BMD after 36 months of testosterone treatment, whereas bone density increased by 3.4, 5.9 and 7.7% respectively in males with basal testosterone levels of 10.4, 6.9 and 2.7 nmol/l respectively (Snyder et al., 1999a (Figure 2) . Thus, clear positive effects of testosterone treatment on BMD are seen in elderly males with severe hypogonadism, whereas this effect is diminished with increasing basal testosterone levels.
Testosterone and behaviour A high endogenous testosterone serum level is usually believed to be associated with extrovert and aggressive behaviour (Brooks and Reddon, 1996) , although this cannot be demonstrated in many studies (Monti et al., 1977; Scaramella and Brown, 1978) . Yet, some studies have found high testosterone levels in violent sexual offenders (Brooks and Reddon, 1996; Studer et al., 1997) , which is the rationale for medical castration in some sexual offenders. Treatment of healthy males with high doses of testosterone (600 mg testosterone cypionate per week) had variable effects on behaviour, but it is noteworthy that almost 20% of the treated men A.Juul and N.E.Skakkebñk showed some manic behaviour during treatment (Pope et al., 2000) .
Testosterone and depression
Men with depression have decreased testosterone levels (Unden et al., 1988; Schweiger et al., 1999) . Testosterone levels as well as the number of CAG repeats within the AR gene were signi®cantly associated with depression (Seidman et al., 2001a) . Therefore, testosterone treatment has been considered for men with selective serotonin re-uptake inhibitor (SSRI)-refractory depression, but did not prove ef®cient (Seidman et al., 2001b) .
Testosterone and sexuality
Hypogonadal men have decreased sexual activity and libido (Skakkebaek et al., 1981; Kwan et al., 1983) . Hypogonadism is a rare cause of erectile dysfunction, which is usually of organic (vascular) or psychological origin (Feldman et al., 1994) . When impotence is treated with non-endocrine therapy, depending on aetiology (psychological, medical or surgical treatment), sexual activity is increased, and at the same time endogenous testosterone levels increase, regardless of the type of therapy (Jannini et al., 1999) . Large cross-sectional studies have not been able to link endogenous testosterone levels with erectile dysfunction or libido in men evaluated because of sexual dysfunction (Krause and Muller, 2000) . Testosterone levels could only to some extent explain changes in sexual function with increasing age in otherwise healthy subjects Perry et al., 2001) , and the testosterone levels required to sustain normal sexual interest in ageing men are rather low .
Testosterone and coronary heart disease
The effect of androgens on the lipid pro®le is of particular interest because it may explain in part the higher prevalence of atherosclerosis in men relative to women. Low total testosterone and high free androgen index are signi®cantly associated with an atherogenic lipid pro®le as shown in several cross-sectional studies (Khaw and Barrett-Connor, 1991; Barrett-Connor, 1992; Zmuda et al., 1997; Gyllenborg et al., 2001 ) suggesting a cardioprotective effect of endogenous testosterone. However, there is much room for confounding in such cross-sectional analyses as many of the variables, such as smoking and body composition, are interdependent. Smoking is much more prevalent among individuals with high testosterone levels. In a cross-sectional study of >500 healthy men, 63% of the men in the upper testosterone quartile were current smokers compared with 33% in the lowest quartile (Gyllenborg et al., 2001) . The exact mechanism behind the association between smoking and testosterone levels (Handa et al., 1997; Gyllenborg et al., 2001; Tamimi et al., 2001 ) remains unknown, but it has been suggested to be due to a behavioural effect of high testosterone, a direct effect of nicotine on testicular function or alternatively an indirect effect on SHBG (English et al., 2001) .
Testosterone may affect the risk of cardiovascular disease by lipid-independent mechanisms. Thus, CAG repeat polymorphism in the AR gene affected not only high density lipoprotein (HDL)-cholesterol syntheses but also arterial vasoreactivity (Zitzmann et al., 2001) . Interestingly, testosterone, at physiological concentrations, induced coronary artery dilatation (Chipman et al., 1997) , thereby having bene®cial effects on exercise-induced myocardial ischaemia (English et al., 2001; Rosano et al., 1999) .
Importantly, prospective follow-up studies have not been able to demonstrate any association between the endogenous testosterone concentration and development of ischaemic heart disease (Contoreggi et al., 1990; Yarnell et al., 1993; Goodman-Gruen and Barrett-Connor, 1996) . Development of myocardial infarction and stroke has been described following supraphysiological doses of testosterone in young athletes (Frankle et al., 1988; McNutt et al., 1988) , but these case study ®ndings cannot for obvious reasons be extrapolated to physiological replacement therapy in hypogonadal men. HDL-cholesterol levels declined after pharmacological testosterone treatment in eugonadal men (Barrett-Connor and Khaw, 1988; Bagatell et al., 1994; Dickerman et al., 1997) , which suggest an unfavourable effect of exogenous testosterone on cholesterol synthesis in otherwise healthy men. Thus, the effect of exogenous testosterone on cardiovascular risk factors in eugonadal men remains uncertain, whereas testosterone treatment of hypogonadal men resulted in lowered total cholesterol levels and unchanged HDLcholesterol levels (Zgliczynski et al., 1996; Tripathy et al., 1998) .
Testosterone and prostate cancer
Prospective studies have shown that a high-normal testosterone serum level seems to be associated with increased risk of prostate cancer (Gann et al., 1996) . Also polymorphisms in the CYP19 gene (Haiman et al., 2001) , 5a reductase gene (Kantoff et al., 1997) and the number of CAG repeats within the AR gene (Giovannucci et al., 1999) were reported to be associated with the risk of prostate cancer. Thus, the individual roles of testosterone, DHT, E 2 or the balance between these hormones with respect to risk of prostate cancer remain unknown, although DHT is considered the main androgen responsible for prostatic growth. Finasteride, a 5a reductase inhibitor that decreases DHT levels, has been shown to decrease the size of the prostate (McConnell et al., 1992) . Testosterone treatment of hypogonadal men results in varying increases in prostate-speci®c antigen (PSA) levels (Guay et al., 2000; Wang et al., 2000b) and development of prostate cancer after androgen substitution therapy has been described (Wang et al., 2000b) . (Snyder et al., 1999 .
Testosterone therapy in elderly males
Different treatment regimens are available and have been evaluated in elderly males. I.m. injections of long-acting testosterone esters such as testosterone enanthate (Testoviron 135±250 mg every 2±4 weeks) have the advantage of improved compliance. However, the pharmacokinetic pro®le of such therapy seem far from physiological (Figure 3) . Treatment with long-acting testosterone esters may result in elevated E 2 levels (Figure 3 ). Excessively high testosterone as well as supranormal E 2 levels are seen in the week after i.m. Testoviron injection in males with hypogonadotrophic hypogonadism (Fisker et al., 2001) . This may lead to¯uctuations in mood, energy level, libido and sexual function. Oral preparations such as testosterone undecanoate must be given daily in high doses (80±160 mg) to exert a biological effect and give rise to supranormal DHT levels in many individuals (Skakkebaek et al., 1981) . The long-term clinical signi®cance of increased DHT levels is unknown. Furthermore, hepatotoxicity of oral preparations is a concern especially when high doses are used. Transdermal delivery systems of testosterone seem more physiological. Testosterone is administered in lower doses (5.0 mg/24 h) compared to oral administration, but is frequently (10%) accompanied by skin irritation. Furthermore, supraphysiological DHT levels are also seen during transdermally administered testosterone (Wang et al., 2000a) . In previous studies of elderly males, the i.m. and transdermal routes more generally have been used (Table I) . Testosterone preparations may differ in the degree to which they convert to DHT or aromatize to E 2 . Few placebo-controlled studies exist on effects of testosterone therapy in elderly males, and the results are summarized in Table I . However, none of these studies is adequately large enough to calculate the risk of adverse events during therapy.
Known adverse effects of HRT in post-menopausal women include an increased risk of breast cancer (Anonymous, 1997) and deep venous thrombosis (Grady et al., 2000) . The indication to start HRT in a woman is therefore individualized, taking climacterial complaints, BMD and familial disposition to osteoporosis, breast cancer and ischaemic heart disease into account. Such an individualized counselling of bene®ts and adverse effects is only possible due to the large number of placebo-controlled and observational trials of risks and bene®ts of HRT in which >50 000 women have participated. Such large studies do not exist for men.
Testosterone and adverse effects
In truly hypogonadal males, appropriate substitution doses of testosterone are rarely associated with side-effects, which do however occur if excessive doses are administered. Furthermore, side-effects may occur more frequently when testosterone levels are normal before therapy. A retrospective analysis of long-term testosterone replacement in 45 elderly males (baseline testosterone 11 nmol/l) demonstrated that 84% tolerated treatment well and reported an improvement of libido. On the other hand~33% discontinued therapy because of side-effects or lack of improvement (Hajjar et al., 1997) .
Prostate cancer should be considered as one of the potential risks of testosterone therapy in elderly males, although there are no studies on which valid risk calculations can be based. Nevertheless, most studies of testosterone therapy in elderly males report on a signi®cant increase in PSA levels, which need to be followed. However, this does not imply that testosterone is involved in the pathogenesis of prostate cancer, but the potential risk that testosterone treatment could stimulate a pre-existing cancer is a concern. As ageing men have a high incidence of occult prostate cancer, de-masking of cancer by androgen therapy is a risk to consider. Consequently, surveillance of prostate function is recommended during testosterone therapy in elderly males. This approach will inevitably result in an increase in the number of patients diagnosed with prostate cancer due to surveillance bias. A few long-term studies based on small numbers of individuals (n = 35±45) did not ®nd any evidence of increased prostate cancer risk after treatment with per-oral testosterone undecanoate or i.m. testosterone enanthate (Gooren, 1994; Hajjar et al., 1997) . Clearly, the presence of a documented prostate cancer is a contraindication to therapy, and large controlled, prospective studies are needed before a valid estimate of prostate cancer risk during testosterone treatment can be stated.
Polycythaemia (haematocrit >50±52%) is a well-recognized complication to testosterone therapy which is reported in most studies (Hajjar et al., 1997; Ferrando et al., 2002) (Table I ). This may have grave consequences in the elderly since increased blood viscosity may lead to thromboembolic events. Thus, phlebotomy or cessation of therapy was required in 24% of hypogonadal men treated with testosterone to reverse the polycythaemia (Hajjar et al., 1997) .
Gynaecomastia may occur during long-term testosterone therapy (Hajjar et al., 1997) , although the incidence of gynaecomastia during teststerone therapy is not known, but can be explained by the high E 2 levels which are seen during testosterone therapy due to aromatase activity (Figure 3) .
Sleep apnoea may develop or worsen during androgen replacement, as evidenced in a few case reports (Matsumoto et al., 1985) . Although the exact mechanism is unknown, the fact that obstructive sleep apnoea is much more prevalent in males compared with females (Block et al., 1979) suggests that androgens may be involved. However, it should be noted that there have been no controlled trials on androgen treatment in elderly men and development of sleep apnoea. Lipid pro®le may be adversely affected, as treatment with some oral preparations decreased HDL-cholesterol and increased low density lipoproteincholesterol to a higher degree compared with i.m. injections (Thompson et al., 1989) , whereas others found opposite and bene®cial effects on HDL-cholesterol by testosterone undecanoate (Uyanik et al., 1997) . Thus, no conclusions can be drawn at present, but lipids should be monitored routinely during therapy. 
Conclusions
Old men with well-documented hypogonadism should be offered androgen replacement therapy. However, in ageing men, climacterial symptoms such as hot¯ushes, sweating, decreased libido, erectile dysfunction, psychomotoric instability, tiredness and decreased vigour are most often not due to hypogonadism, and therefore such symptoms may not change during androgen substitution. Total testosterone levels show modest variation with age, but due to the increase in SHBG, the free androgen index decreases slowly with increasing age. In addition, LH levels increase with advancing age. In severe hypogonadal men, symptoms such as fatigue, decreased libido and erectile dysfunction are signi®cantly improved during therapy. Male hypogonadism is associated with osteoporosis and increased fracture risk on which testosterone therapy has bene®cial effects. There is no evidence of androgen therapy decreasing the risk of heart disease. By contrast, testosterone therapy may have unfavourable effects on cardiovascular risk factors. Importantly, testosterone treatment has been associated with adverse effects like polycythaemia, gynaecomastia, aggression and prostate cancer, but the actual incidence of these side-effects is unknown. Thus, there is a need for large controlled trials before individual councelling of possible bene®ts and risk to the elderly male is possible, in analogy with what is offered to the peri-menopausal woman. At present we simply do not know the size of the potential risks of long-term testosterone therapy in elderly`normal' males. All we can say is that the`andropause' clearly does not exist. The recent report from the National Institute of Aging Advisory Panel concluded that we need additional data on how to select elderly men who would bene®t from testosterone therapy (i.e. serum testosterone <3.5, <6.9 or <10.3 nmol/l?). Furthermore, the advisory panel recommended that large, long-term (3±5 years) placebo-controlled (Phase III) trials should be conducted to evaluate the risks and bene®ts of such therapy thoroughly (Anonymous, 1997) . In conclusion, testosterone should be offered to males at all ages when they are diagnosed as being severely hypogonadal, but we have to bear in mind that the de®nition of hypogonadism in the ageing male has been insuf®cient up to now, and must be based on large age-dependent reference ranges for testosterone levels. The widespread use of testosterone in an elderly male population outside controlled clinical trials seems to be inappropriate at this point in time.
